Top Markets
Coin of the day
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
Classement en actions #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Prix de l'action
$7.12
Dernière synchronisation: 2023-03-08
Capitalisation boursière
$117.03M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
GB
Échange F-star Therapeutics, Inc. (FSTX)

Catégorie

EPS pour F-star Therapeutics, Inc. (FSTX)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de F-star Therapeutics, Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de F-star Therapeutics, Inc. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH